Ezlopitant

Ezlopitant
Clinical data

Routes of administration	By mouth
ATC code	none
Legal status
Legal status	In general: uncontrolled
Pharmacokinetic data
Excretion	Urine (32%), Feces (51%)
Identifiers
IUPAC name (2S,3S)-2-Benzhydryl-N-[(5-isopropyl-2-methoxy-phenyl)methyl]quinuclidin-3-amine
Synonyms	CJ-11,974; (2S,3S)-2-Diphenylmethyl-3-[(5-isopropyl-2-methoxybenzyl)amino]quinuclidine
CAS Number	147116-64-1
PubChem CID	188927
IUPHAR/BPS	5751
ChemSpider	164166
UNII	3L098A8MPY
ChEMBL	CHEMBL515966
Chemical and physical data
Formula	C₃₁H₃₈N₂O
Molar mass	454.65 g/mol
3D model (Jmol)	Interactive image
SMILES COc1ccc(cc1CN[C@H]2C3CCN(CC3)[C@H]2C(c4ccccc4)c5ccccc5)C(C)C
InChI InChI=1S/C31H38N2O/c1-22(2)26-14-15-28(34-3)27(20-26)21-32-30-25-16-18-33(19-17-25)31(30)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24/h4-15,20,22,25,29-32H,16-19,21H2,1-3H3/t30-,31-/m0/s1 Key:XPNMCDYOYIKVGB-CONSDPRKSA-N

Ezlopitant (INN, code name CJ-11,974) is an NK₁ receptor antagonist. It has antiemetic and antinociceptive effects.Pfizer was developing ezlopitant for the treatment of irritable bowel syndrome but it appears to have been discontinued.